MHRA and NHS Alert:
Publication of an interim position statement: Tocilizumab for patients admitted to ICU with COVID-19 Pneumonia (Adults)

27 November 2020

Following early positive signals of benefit from the immune modulation therapy domain of the REMAP-CAP platform trial, a UK wide position statement has been agreed to support off-label prescribing and access to tocilizumab, administered intravenously, for eligible COVID positive patients in the intensive care setting. The interim position statement will be reviewed as further evidence becomes available, including from the REMAP-CAP trial. Please click here for further information.

ENDS